NASDAQ : RARE
-$0.98 (-3.77%)
NASDAQ
Emil D. Kakkis
Biotechnology
Healthcare
RARE
1371
US
USD
-5.08
2.02
1.85
0.54
0.00
$673M
3.68
-10.66
-5.05
-4.84
-$5.83
-$575M
-91.03%
-90.46%
1566.94%
-47.02%
-4.09
0.84
0.84
$43.00
$67.00
$30.00
2/5
33 Analysts
-41.86%
-4.60
2/9
$332M
$1.3B
$1.52B
-$537.36M
$3.58B
5.35
-7.12
2.02
1566.94%
-53.86%
-23.32%
-19.04%
109 days
| Name | Title |
|---|---|
| Ernie W. Meyer | Chief Human Resources Officer & Executive Vice President |
| John Richard Pinion | Chief Quality Operations Officer & Executive Vice President of Translational Sciences |
| Vimal Srivastava | Senior Vice President of Business Development & Alliance Management |
| Emil D. Kakkis | Founder, President, Chief Executive Officer & Director |
| Eric Crombez | Chief Medical Officer & Executive Vice President |
| Dennis Karl Huang | Chief Technical Operations Officer and Executive Vice President of Gene Therapy Operations |
| Howard Horn | Executive Vice President of Corporate Strategy & Chief Financial Officer |
| Theodore A. Huizenga | Senior Vice President, Corporate Controller & Principal Accounting Officer |
| Karah Herdman Parschauer | Chief Legal Officer & Executive Vice President of Corporate Affairs |
| Erik Harris | Executive Vice President & Chief Commercial Officer |
No votes yet today — be the first to share your view!
About Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets. The company's portfolio of marketed biologic products addresses several serious diseases. This includes Crysvita (burosumab), an antibody that targets fibroblast growth factor 23, used to treat X-linked hypophosphatemia and tumor-induced osteomalacia. Mepsevii offers enzyme replacement therapy for both pediatric and adult patients suffering from Mucopolysaccharidosis VII. Dojolvi is available for individuals with long-chain fatty acid oxidation disorders, while Evkeeza (evinacumab) provides a treatment option for homozygous familial hy ... percholesterolemia. Ultragenyx also boasts a robust pipeline of investigational therapies. Notable candidates include DTX401, an adeno-associated virus 8 (AAV8) gene therapy for glycogen storage disease type Ia, and DTX301, another AAV8 gene therapy aimed at ornithine transcarbamylase deficiency. Other promising developments feature UX143, a human monoclonal antibody for osteogenesis imperfecta; GTX-102, an antisense oligonucleotide designed for Angelman syndrome; UX701, targeting Wilson disease; and UX053, in development for glycogen storage disease type III. To advance its research and development efforts, Ultragenyx Pharmaceutical Inc. maintains strategic collaboration and licensing agreements with numerous partners, such as Kyowa Kirin Co., Ltd., Saint Louis University, REGENXBIO Inc., Bayer Healthcare LLC, GeneTx, Mereo, University of Pennsylvania, Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc., and Daiichi Sankyo Co., Ltd. The company was founded in 2010 and operates from its headquarters in Novato, California.
Ultragenyx to Host Conference Call for Second Quarter 2026 Financial Results and Corporate Update
2026-07-28 16:05:00
NOVATO, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Tuesday, August 4, 2026, to discuss its financial results and corporate update for the quarter ending June 30, 2026.
Earnings Preview: Ultragenyx (RARE) Q2 Earnings Expected to Decline
2026-07-28 11:06:26
Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Entropy Technologies LP Grows Position in Ultragenyx Pharmaceutical Inc. $RARE
2026-07-27 04:04:03
Entropy Technologies LP grew its position in Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) by 80.9% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 109,727 shares of the biopharmaceutical company's stock after acquiring an additional 49,086 shares during the quarter.
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-07-24 16:30:00
NOVATO, Calif., July 24, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 65,886 restricted stock units of the company's common stock to 39 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company's board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of July 16, 2026, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
Brazilian Rare Earths June 2026 Quarterly Report
2026-07-23 08:30:00
SYDNEY, July 23, 2026 (GLOBE NEWSWIRE) -- Brazilian Rare Earths Limited (ASX: BRE / OTCQX: BRELY) ('BRE') is pleased to report progress during the quarter ended 30 June 2026. Highlights during and subsequent to the end of the quarter include: VELHINHAS AIRBORNE GEOPHYSICS AND DRILLING UNLOCKS +9 KM RARE EARTH CORRIDOR IN THE MONTE ALTO DISTRICT New District-Scale Growth Corridor: High-resolution airborne geophysics defined more than 9 km of cumulative exploration corridors across the Velhinhas project, beginning ~5 km south of the ultra-high-grade Monte Alto Deposit and extending rare earth mineralisation to over 8 km south of Monte Alto Multiple Parallel Exploration Trends: The survey confirmed four large-scale north-northeast trending mineralised corridors, converting numerous ultra-high-grade surface results into a district-scale exploration model analogous with the Sulista district opportunity Drilling Results Confirm High-Grade Mineralisation: Reconnaissance diamond drilling returned grades of 19.6% TREO, 33,607 ppm NdPr, 1,463 ppm Dy₂O₃, 248 ppm Tb₄O₇, 7,431 ppm Y₂O₃ and 1,087 ppm U₃O₈ Critical Mineral Grades: High-grade assays are accompanied by NdPr, DyTb, yttrium, niobium, scandium, tantalum and uranium, consistent with BRE's high-value REE-Nb-Sc-Ta-U systems at Monte Alto and Sulista Monte Alto District Growth Accelerates: Velhinhas expands the Monte Alto growth story, highlighting the potential for a district-scale mineral system extending south from the ultra-high-grade Monte Alto Deposit EXCEPTIONAL YTTRIUM-RICH HEAVY RARE EARTH DRILL RESULTS EXPAND THE MONTE ALTO DISTRICT Exceptional heavy rare earth grades: MADD0210 returned 2.5 m at 7.5% TREO from 6.0 m, including 1.3 m at 10.9% TREO from 7.2 m, with 58,249 ppm (5.8%) Y2O3, 4,135 ppm Dy2O3, 488 ppm Tb4O7 and 1,588 ppm U3O8 New high-grade, heavy rare earth target remains open: Auger hole STU2478, located ~200 m southwest of the initial diamond drilling, returned 12 m at 8.7% TREO from 18 m to end of hole, including 1,004 ppm DyTb and 0.44% Y2O3.
Fifth Third Bancorp Acquires New Holdings in Ultragenyx Pharmaceutical Inc. $RARE
2026-07-22 03:47:27
Fifth Third Bancorp bought a new stake in Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 110,272 shares of the biopharmaceutical company's stock, valued at approximately $2,310,000. Fifth Third Bancorp owned about 0.11%
2026-07-21 02:30:00
LEADING EDGE MATERIALS ADVANCES MIDSTREAM PROCESSING STRATEGY FOR THE NORRA KÄRR HEAVY RARE EARTH ELEMENTS PROJECT
2026-07-15 11:33:00
SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) against certain of its officers and directors for alleged breaches of fiduciary duty.
Frequently Asked Questions
What is the current Ultragenyx Pharmaceutical Inc. (RARE) stock price?
Ultragenyx Pharmaceutical Inc.(NASDAQ:RARE) stock price is $25 in the last trading session. During the trading session, RARE stock reached the peak price of $39.89 while $18.29 was the lowest point it dropped to. The percentage change in RARE stock occurred in the recent session was --3.77% while the dollar amount for the price change in RARE stock was -$0.98.
RARE's industry and sector of operation?
The NASDAQ listed RARE is part of Biotechnology industry that operates in the broader Healthcare sector.
Who are the executives of RARE?
Ernie W. Meyer
| Chief Human Resources Officer & Executive Vice President
John Richard Pinion
| Chief Quality Operations Officer & Executive Vice President of Translational Sciences
Vimal Srivastava
| Senior Vice President of Business Development & Alliance Management
Emil D. Kakkis
| Founder, President, Chief Executive Officer & Director
Eric Crombez
| Chief Medical Officer & Executive Vice President
How many employees does RARE have?
Number of RARE employees currently stands at 1371. RARE operates from 60 Leveroni Court, Novato, CA 94949, US.
Link for RARE official website?
Official Website of RARE is: https://www.ultragenyx.com
How do I contact RARE?
RARE could be contacted at phone #415 483 8800 and can also be accessed through its website. RARE operates from 60 Leveroni Court, Novato, CA 94949, US.
How many shares of RARE are traded daily?
The average number of RARE shares traded daily for last 3 months was 2.18M.
What is the market cap of RARE currently?
The market value of RARE currently stands at $2.46B with its latest stock price at $25